BIA
MYGN icon

Bell Investment Advisors’s Myriad Genetics MYGN Stock Holding History

Bell Investment Advisors’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-48
Closed -$1.12K – 1963
2023
Q1 		$1.12K Buy
+48
New +$975 ﹤0.01% 1516

Other funds holding MYGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GCM
Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Bell Investment Advisors's MYGN Position: Q2 2023 in Review

Bell Investment Advisors sold out of Myriad Genetics (MYGN) in Q2 2023, closing a stake of 48 shares — an estimated $1.12K sold.

Bell Investment Advisors first reported a position in MYGN in Q1 2023 and held it in 1 quarter. The position peaked at $1.12K in Q1 2023. 188 funds tracked by Wall St. Rank hold MYGN as of Q2 2023.

  • Bell Investment Advisors reported no remaining Myriad Genetics position as of Q2 2023 after selling out during the quarter.
  • Bell Investment Advisors sold 48 Myriad Genetics shares in Q2 2023, an estimated $1.12K.
  • Bell Investment Advisors first reported a position in Myriad Genetics in Q1 2023 and held it in 1 quarter.
  • Bell Investment Advisors's Myriad Genetics position peaked at $1.12K in Q1 2023.
  • 188 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2023.

Based on Bell Investment Advisors's 13F filing for Q2 2023, filed 9 Aug 2023.